A Double‐Blind, Placebo‐Controlled, Single‐Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HT‐101, an RNAi Therapeutic Targeting HBV Infection. - Zhang, Jianxiong; Li, Jiangshuo; Wu, Le; Song, Yuqin; Li, Xiao; Gao, Qiannan; Wu, Jingxuan; Wang, Dong; Zhang, Zhipeng; Zhang, Shanzhong; Ding, Lijuan; Ma, Yanqin; et al. (Clinical Pharmacology in Drug Development, 2025)